<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>NETPHARM Algorithm</title>
  <style>
    body {
      font-family: Arial, sans-serif;
      padding: 40px;
      background-color: #f5f6f7;
    }
    h1 {
      color: #0a2f66;
    }
    .box {
      background: #eec9e7;
      border: 2px solid #ccc;
      padding: 20px;
      margin-top: 20px;
      border-radius: 10px;
    }
    .recommendation-box {
      padding: 15px;
      border-radius: 8px;
      margin-top: 15px;
      border: 1px solid #ccc;
      white-space: pre-wrap;
    }
    .frailty, .heart, .renal { background-color: #ffc000; }
    .hepatic { background-color: #92d050; }

    select, label, input[type=checkbox] {
      font-size: 16px;
    }
    #logo {
      height: 4cm;
      width: 4cm;
      vertical-align: middle;
      margin-right: 10px;
    }
    #painType {
      margin-top: 0.25cm;
    }
    label[for="painType"], label[for="medication"] {
      display: block;
      margin-bottom: 0.25cm;
    }
    .references {
      font-size: 10px;
      margin-top: 40px;
      color: #333;
    }
    .checkbox-group label {
      display: block;
      margin: 5px 0;
    }
    @media (max-width: 600px) {
      body {
        padding: 15px;
      }
      h1 {
        font-size: 20px;
      }
      #logo {
        height: 2.5cm;
        width: 2.5cm;
        display: block;
        margin: 0 auto 10px;
      }
      .box {
        padding: 15px;
        font-size: 14px;
      }
      select, label {
        font-size: 14px;
        width: 100%;
      }
    }
  </style>
</head>
<body>
  <img src="netpharm_logo_znacka.png" id="logo" alt="NETPHARM Logo">

  <h1>Optimising the Use of Psychotropic Coanalgesics in Frail Older Adults<br>
  with Hepatorenal and/or Cardiorenal Syndromes and Neuropathic Pain</h1>
  <p><em>A Clinical Algorithm Developed Under the NETPHARM Project</em></p>
  <p>This project was supported by the NETPHARM project (New Technologies for Translational Research in Pharmaceutical Sciences).</p>
  <p>Project ID CZ.02.01.01/00/22_008/0004607, co-funded by the European Union.</p>

  <div class="box">
    <label for="painType"><strong>1. Select type of neuropathic pain:</strong></label>
    <select id="painType" onchange="showMedications()">
      <option value="">-- Choose --</option>
      <option value="diabetic">Diabetic neuropathy</option>
      <option value="postherpetic">Postherpetic neuropathy</option>
      <option value="trigeminal">Trigeminal neuralgia</option>
      <option value="central">Central pain</option>
    </select>

    <div id="medicationsBox" style="margin-top: 0.25cm; display: none;">
      <label for="medication"><strong>2. Select recommended medication:</strong></label>
      <select id="medication" onchange="showComorbidities()"></select>
    </div>

    <div id="comorbidityBox" style="margin-top: 20px; display: none;">
      <label><strong>3. Select comorbidities or patient status:</strong></label><br>
      <div class="checkbox-group">
        <label><input type="checkbox" value="renal"> Renal Impairment</label>
        <label><input type="checkbox" value="hepatic"> Hepatic Impairment</label>
        <label><input type="checkbox" value="cardiac"> Heart Failure</label>
        <label><input type="checkbox" value="frailty"> Frailty Syndrome</label>
      </div>
      <button onclick="showMultipleRecommendations()">Show Recommendations</button>
    </div>

    <div id="recommendation" style="margin-top: 20px;"></div>
  </div>

  <div class="references">
    <strong>Guideline References:</strong><br>
    EFNS 2010 – Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. <em>Eur J Neurol.</em> 2010 Sep;17(9):1113-e88. doi:10.1111/j.1468-1331.2010.02999.x. PMID: 20402746.<br><br>
    NICE CG173 – National Institute for Health and Care Excellence. Neuropathic pain in adults: pharmacological management in non-specialist settings [CG173]. London: NICE; 2013 [updated 2020 Dec]. Available from: https://www.nice.org.uk/guidance/cg173<br><br>
    CPS 2022 – Mu A, Weinberg E, Moulin DE, Clarke H. Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement. <em>Can Fam Physician.</em> 2022 Nov;68(11):844–50.<br><br>
    AAN 2022 – Price R, Smith D, Franklin GM, Gronseth G, Pignone M, David WS, et al. Oral and topical treatment of painful diabetic polyneuropathy: Practice guideline update summary. <em>Neurology.</em> 2022 Jan 4;98(1):31–43. doi:10.1212/WNL.0000000000013038.
  </div>

  <script>
    const drugOptions = {
      diabetic: [
        "Amitriptyline (EFNS, NICE, AAN, CPS)",
        "Duloxetine (EFNS, NICE, AAN, CPS)",
        "Venlafaxine (EFNS, NICE, AAN, CPS)",
        "Gabapentin (EFNS, AAN, CPS)",
        "Pregabalin (EFNS, NICE, AAN, CPS)"
      ],
      postherpetic: [
        "Amitriptyline (EFNS, NICE, CPS)",
        "Duloxetine (NICE)",
        "Venlafaxine (NICE)",
        "Gabapentin (EFNS, CPS)",
        "Pregabalin (EFNS, NICE, CPS)"
      ],
      trigeminal: [
        "Carbamazepine (EFNS, NICE, CPS)"
      ],
      central: [
        "Amitriptyline (EFNS, NICE)",
        "Duloxetine (NICE)",
        "Venlafaxine (NICE)",
        "Gabapentin (EFNS)",
        "Pregabalin (EFNS, NICE)"
      ]
    };

    function showMedications() {
      const painType = document.getElementById('painType').value;
      const medicationBox = document.getElementById('medicationsBox');
      const medicationSelect = document.getElementById('medication');
      const comorbidityBox = document.getElementById('comorbidityBox');
      const recommendation = document.getElementById('recommendation');

      medicationSelect.innerHTML = '<option value="">-- Choose --</option>';
      recommendation.innerHTML = '';
      comorbidityBox.style.display = 'none';

      if (drugOptions[painType]) {
        drugOptions[painType].forEach(drug => {
          const option = document.createElement('option');
          option.textContent = drug;
          option.value = drug.split(' ')[0].toLowerCase();
          medicationSelect.appendChild(option);
        });
        medicationBox.style.display = 'block';
      } else {
        medicationBox.style.display = 'none';
      }
    }

    function showComorbidities() {
      document.getElementById('comorbidityBox').style.display = 'block';
      document.getElementById('recommendation').innerHTML = '';
    }

    function showMultipleRecommendations() {
      const med = document.getElementById('medication').value;
      const checkboxes = document.querySelectorAll('#comorbidityBox input[type=checkbox]');
      let output = '';
      checkboxes.forEach(cb => {
        if (cb.checked) {
          const comorbidity = cb.value;
          let content = '';
          let cssClass = comorbidity;

          if (med === 'gabapentin') {
            if (comorbidity === 'frailty') {
              content = `Gabapentin poses fall and CNS toxicity risk (dizziness, sedation, ataxia). Avoid in non-neuropathic pain (STOPP/START). Monitor cognition, gait, and sedation.`;
            } else if (comorbidity === 'cardiac') {
              content = `Gabapentin may worsen fluid retention and heart failure. Monitor for edema and dyspnea.`;
            } else if (comorbidity === 'hepatic') {
              content = `Gabapentin may cause peripheral edema (2–8%). Possible to use with caution. Monitor edema and ascites.`;
            } else if (comorbidity === 'renal') {
              content = `<strong>Risks:</strong> risk of overdose due to cumulation of the drug\n<strong>Risk monitoring:</strong> monitor renal function regularly\n<strong>Dose adjustment:</strong>\neGFR ≥80 ml/min: daily dose 900–3600 mg (in 3 daily doses),\neGFR 50–79 ml/min: 600–1800 mg/day (in 3 daily doses),\neGFR 30–49 ml/min: 300–900 mg/day (in 3 daily doses),\neGFR 15–29 ml/min: 150 mg on alternate days – 600 mg/day (in 3 daily doses),\neGFR <15 ml/min: 150 mg on alternate days – 300 mg/day; reduce daily dose in, proportion to creatinine clearance.\nIn anuric patients on hemodialysis, an initial dose of 300–400 mg/day is recommended, followed by 200 to 300 mg of gabapentin after every 4 hours of dialysis. On non-dialysis days, gabapentin therapy should not be administered.\n<strong>Recommendation:</strong> use with caution\nGabapentin may be administered provided that renal function is closely monitored and appropriate dose adjustments are made, especially when eGFR is below 60 ml/min. This agent should be used with caution in patients showing unstable or progressively declining renal function, AKI, and nephrotic syndrome.`;
            } else {
              content = 'No specific recommendation available.';
            }
          } else {
            content = 'No specific recommendation available for this combination.';
          }

          output += `<div class='recommendation-box ${cssClass}'><strong>${cb.nextSibling.textContent.trim()}:</strong> ${content}</div>`;
        }
      });
      document.getElementById('recommendation').innerHTML = output;
    }
  </script>
</body>
</html>
